That's not a health care system. It's a hostage crisis. Why are these drugs so expensive? Because for too long, government bureaucracy and regulatory barriers have protected monopolies and stifled competition. The FDA's outdated and burdensome approval process has slowed down the entry of biosimilars. to lower cost, equally safe alternatives to Brin and biologics. And even when biosimilars do get approved, current laws often prevent pharmacists or patients from substituting them for the patients who would benefit from a more affordable option. (04:19–04:27)
CLAIM
Asserts that the FDA's approval process has hindered biosimilar market entry.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
